Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Advanced Anal Squamous Cell Cancer
NCT07680088Phase 2Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in anal squamous cell carcinoma (SCCA), sponsored by UT Southwestern Medical Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT07680088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680088.